<DOC>
	<DOCNO>NCT00688090</DOCNO>
	<brief_summary>A dose comparison multi-component active immunotherapy design stimulate immune reaction specific tumor associate antigens highly express melanoma .</brief_summary>
	<brief_title>Safety Immune Response Multi-component Immune Based Therapy ( MKC1106-MT ) Patients With Melanoma .</brief_title>
	<detailed_description>The multi-component active immunotherapy , MKC1106-MT , consist 1 plasmid dose 2 peptide dos design stimulate immune reaction two tumor associate antigen ( Melan-A tyrosinase ) . The plasmid component administer Days 1,4 , 15 18 treatment cycle follow administration peptide Days 29 32 treatment cycle . All component administer separately superficial inguinal lymph node ultrasound guidance .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Confirmed diagnosis locally advance metastatic melanoma ( American Joint Committee Cancer [ AJCC 6th edition ] stage IIIB , IIIC IV ) refractory standard therapy curative standard therapy exists . Patients enrol Phase 2 portion trial must measurable disease RECIST criterion ECOG performance status 0 1 Life expectancy = 3 month 18 year age old screen evaluation Positive HLAA2 , precisely , express A*0201 assess DNA type Tumor material prior biopsy / surgical resection available analysis expression melanoma specific antigens Adequate bone marrow reserve evidence : Absolute neutrophil count ( ANC ) = 1,000/ ? L &amp; Platelet count = 75,000/ ? L Adequate renal function evidence : serum creatinine = 1.5 mg/dL Adequate hepatic function evidence : Serum total bilirubin = 2.0 mg/dL &amp; SGOT/SGPT = 3 time ULN reference lab ( = 5 ULN reference lab subject know hepatic metastasis ) Subjects must recover least baseline Grade 1 toxicity effect prior surgery , radiotherapy therapy include limited chemotherapy Women childbearing potential well fertile men partner must agree use effective method contraception abstain sexual intercourse clinical trial 90 day follow last dose investigational new drug Subjects must able provide inform consent participation clinical trial protocolspecific clinical trial procedure perform No systemic infection require treatment Symptomatic brain metastasis and/or progression CNS metastases within past 4 week ; patient treat CNS metastasis ( surgery and/or radiation ) , neurologically stable , longer take glucocorticoid , eligible Subjects autoimmune disorder , include , limited : systemic lupus erythematosus , rheumatoid arthritis , systemic sclerosis , Sjogren 's syndrome , mixed connective tissue disease , ankylose spondylitis , Hashimoto 's thyroiditis , bullous pemphigus , sarcoidosis , Beh√ßet 's syndrome , vasculitis , familial Mediterranean fever , Wegener 's granulomatosis Goodpasture 's syndrome Positive HIV , hepatitis B hepatitis C antibody test Subjects underwent allogeneic transplant New York Heart Association Grade III IV congestive heart failure Medical , sociological psychological condition may compromise compliance participation clinical trial interfere interpretation result Subjects take drug negatively affect immune function systemic corticosteroid immunomodulatory drug include , limited , interferonalpha , interferonbeta , interleukin2 , etanercept , infliximab , tacrolimus , cyclosporine , mycophenolic acid , alefacept efalizumab , within one month precede screen Subjects lactate , pregnant , plan become pregnant within three month treatment completion Subjects receive investigational drug within precede four week enrollment Subjects affect inguinal lymph node ( metastatic process ) lack inguinal lymph node ( resection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Immunotherapy , Melanoma , Cancer Vaccine</keyword>
</DOC>